LOS ANGELES, Aug. 6 /PRNewswire/ -- Vista Partners announced today that it has updated coverage and has issued a $3.57 price target on Inovio Biomedical Corporation (Amex: INO). "The proposed merger of Inovio and VGX would create a comprehensive DNA company that can create and deliver therapeutic agents and positions Inovio/VGX, based on further development progress, to move toward the same valuation arena as other gene therapy companies," said Ross Silver, Director of Research for Vista Partners. For more information and to download the free report, please visit the Vista Partners website at http://www.vistap.com and click on the "download research" icon.
About Vista Partners:
Vista Partners provides independent, equity research to institutional and individual investors, with a focus on publicly traded small capitalization companies. With offices in Los Angeles and San Francisco, Vista Partners is one of the fastest growing independently owned equity research firms. Vista Partners professional staff has backgrounds in finance, corporate communications and investment banking. More information is available at http://www.vistap.com.
About Inovio Biomedical Corporation:
Inovio Biomedical (Amex: INO) is focused on developing multiple
DNA-based immunotherapies. Inovio is a leader in developing human
applications of electroporation using brief, controlled electrical pulses
to increase cellular uptake of a useful biopharmaceutical. Interim human
data has shown that Inovio's DNA delivery technology can significantly
increase gene expression and immune responses from DNA vaccines.
Immunotherapy partners include Merck, Wyeth, Vical, University of
Southampton, Moffitt Cancer Center, the U.S. Army, National Cancer
Institute, and International Aids Vaccine Initiative. Inovio's technology
is protected by an extensive patent portfolio covering in vivo
electroporation. More information is available at http://www.inovio.com.
Vista Partners LLC
|SOURCE Vista Partners|
Copyright©2008 PR Newswire.
All rights reserved